Personalized Letter With Cancer Information Service Support or a Standard Reminder Letter in Women Scheduled for Colposcopy After an Abnormal Pap Test
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00873288|
Recruitment Status : Unknown
Verified March 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : April 1, 2009
Last Update Posted : January 28, 2010
RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their follow-up colposcopy appointment.
PURPOSE: This randomized clinical trial is studying a personalized letter with Cancer Information Service support to see how well it works compared with a standard reminder letter in women scheduled for colposcopy after an abnormal Pap test.
|Condition or disease||Intervention/treatment|
|Precancerous Condition||Other: informational intervention Other: questionnaire administration|
- Compare the effect of a usual care mailing intervention vs a Cancer Information Service (CIS) support mailing intervention on the likelihood that women with an abnormal Pap test will keep their medical follow-up appointments and be satisfied with how they talk to their provider.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 intervention arms.
- Arm I (Usual-care mailing intervention): Patients receive a generic letter reminding them of their follow-up colposcopy appointment.
- Arm II (Cancer Information Service [CIS] support mailing intervention): Patients receive a targeted letter reminding them of their follow-up colposcopy appointment, asking them or someone they designate to call the CIS, and suggesting some questions to ask the CIS about colposcopies and Pap tests.
At their follow-up appointments, all patients undergo an exit interview to compare patient satisfaction between the 2 interventions. Patients in arm II also answer questions about their CIS experience, and if the intervention made their follow-up visit less difficult.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||500 participants|
|Primary Purpose:||Health Services Research|
|Official Title:||Activating Collaborative CIS Support Via Targeted Provider Mailing|
|Study Start Date :||October 2006|
|Estimated Primary Completion Date :||September 2009|
- Patient satisfaction in the 2 interventions
- CIS experience of patients in arm II and the effect of the intervention on their follow-up colposcopy
- Attendance at a follow-up colposcopy appointment within 6 months of their Pap test
- Latency between the Pap test and the colposcopy appointment
- Number of CIS callers who provided the specific codes listed in the intervention letter
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00873288
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center at Northwestern University||Recruiting|
|Chicago, Illinois, United States, 60611-3013|
|Contact: Clinical Trials Office - Robert H. Lurie Comprehensive Cancer 312-695-1301 email@example.com|
|Erie Family Health Center||Recruiting|
|Chicago, Illinois, United States, 60622|
|Contact: Contact Person Not Available firstname.lastname@example.org|
|Principal Investigator:||Bonnie Spring, PhD||Robert H. Lurie Cancer Center|